COPD Exacerbation Frequency, Pharmacotherapy and Resource Use: An Observational Study in UK Primary Care

References

• Office for National Statistics. Mortality Statistics: Deaths registered in England and Wales 2010 (Series DR). Office for National Statistics [Internet]. Available from http://www.ons.gov.uk/ons/rel/vsob1/mortality-statistics–deaths-registered-in-england-and-wales–series-dr-/2010/index.html. Accessed 13/09/2012.
   Google Scholar
• National Clinical Guideline Centre. (2010) Chronic Obstructive Pulmonary Disease –Management of chronic obstructive pulmonary disease in adults in primary and secondary care. London: National Clinical Guideline Centre. Available from: http://guidance.nice.org.uk/CG101/Guidance/pdf/English. Accessed 16/01/2013
   Google Scholar
• World Health Organization (WHO) 2006. Burden of COPD. World Health Organization [Internet]. Available from http://www.who.int/respiratory/copd/burden/en/index.html. Accessed 13/09/2012
   Google Scholar
• Department of Health 2011. An Outcomes Strategy for Chronic Obstructive Pulmonary Disease (COPD) and Asthma in England. Department of Health [Internet]. Available from: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_127974. Accessed 13/09/2012.
   Google Scholar
• Britton M. The burden of COPD in the U.K.: results from the Confronting COPD survey. Respir Med 2003 Mar; 97 Suppl C:S71–79.
   PubMed Web of Science ®Google Scholar
• Jones RC, Dickson-Spillman M, Mather MJ, Marks D, Shackell BS. Accuracy of diagnostic registers and management of chronic obstructive pulmonary disease: the Devon primary care audit. Respir Res 2008 Aug; 9(1):62.
   PubMedGoogle Scholar
• British Heart Foundation statistics. Prevalence of CHD, stroke, myocardial infarction and angina, by sex and age, England 2006. Available from http://www.bhf.org.uk/research/heart-statistics/morbidity/prevalence.aspx. Accessed 07/08/2013.
   Google Scholar
• The NHS Information Centre for Health and Social Care. Disease Prevalence –Quality and Outcomes Framework (QOF) for April 2011-March 2012, England. Available from http://www.diabetes.org.uk/Professionals/Publications-reports-and-resources/Reports-statistics-and-case-studies/Reports/Diabetes-prevalence-2012-March-2013/. Accessed 07/08/2013
   Google Scholar
• Hardin M, Silverman EK, Barr RG, Hansel NN, Schroeder JD, Make BJ, Crapo J, Hersh CP and the COPD Gene Investigators. The clinical features of the overlap between COPD and asthma. Respir Res 2011 Sep; 12:127.
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Seemungal TA, Patel IS, Lloyd-Owen SJ, Wilkinson TM, Wedzicha JA. Longitudinal changes in the nature, severity and frequency of COPD exacerbations. Eur Respir J 2003 Dec; 22(6):931–936.
   PubMed Web of Science ®Google Scholar
• Jones PW, Willits LR, Burge PS and on behalf of the Inhaled Steroids in Obstructive Lung Disease in Europe study investigators. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003 Jan; 21(1):68–73.
   PubMed Web of Science ®Google Scholar
• Hurst JR, Vestbo J, Anzueto A, Locantore N, MÜllerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, MacNee W, Calverley P, Rennard S, Wouters EF, Wedzicha JA for the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010 Sep; 363:1128–1138.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Murio C, Guerrero T, Gisbert R. Costs of chronic bronchitis and COPD: a 1-year follow-up study. Chest 2003 Mar; 123(3):784–791.
   PubMed Web of Science ®Google Scholar
• Halpern MT, Stanford RH, Borker R. The burden of COPD in the U.S.A.: results from the confronting COPD survey. Respir Med 2003 Mar; 97 Suppl C:S81–89.
   PubMed Web of Science ®Google Scholar
• Miller JD, Foster T, Boulanger L, Chace M, Russell MW, Marton JP, Menzin J. Direct costs of COPD in the U.S.: an analysis of Medical Expenditure Panel Survey (MEPS) data. COPD 2005 Jan; 2(3):311–318.
   PubMedGoogle Scholar
• Andersson F, Borg S, Jansson SA, Jonsson AC, Ericsson S, PrÜtz C. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 2002 Sep; 96(9):700–708.
   PubMed Web of Science ®Google Scholar
• Strassels SA, Smith DH, Sullivan SD, Mahajan PS. The costs of treating COPD in the United States. Chest 2001 Feb; 119(2):344–352.
   PubMed Web of Science ®Google Scholar
• Gerdtham UG, Andersson LF, Ericsson A, Borg S, Jansson SA, Rönmark E, Lundbäck B. Factors affecting chronic obstructive pulmonary disease (COPD)-related costs: a multivariate analysis of a Swedish COPD cohort. Eur J Health Econ 2009 May; 10(2):217–226.
   PubMed Web of Science ®Google Scholar
• Jansson SA, Andersson F, Borg S, Ericsson A, Jönssen E, Lundbäck B. Costs of COPD in Sweden according to disease severity. Chest 2002 Dec; 122(6):1994–2002.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Ferrer M, Pont A, Zalacain R, Alvarez-Sala JL, Masa F, Verea H, Murio C, Ros F, Vidal R. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 2004 May; 59:387–395.
   PubMed Web of Science ®Google Scholar
• Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998 May; 157(5 Pt 1):1418–1422.
   PubMed Web of Science ®Google Scholar
• Cote CG, Dordelly LJ, Celli BR. Impact of COPD exacerbations on patient-centred outcomes. Chest 2007 Mar; 131(3):696–704.
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. The relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002 Oct; 57(10):847–852.
   PubMed Web of Science ®Google Scholar
• Jenkins CR, Jones PW, Calverley PM, Celli B, Anderson JA, Ferguson GT, Yates JC, Willits LR, Vestbo J. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009 Jun; 10:59.
   PubMed Web of Science ®Google Scholar
• Calverley P, Pauwels RA, Jones PW, Anderson JA, Vestbos J. The severity of airways obstruction as a determinant of treatment response in COPD. Int J Chron Obstruct Pulmon Dis 2006 May; 1(3):209-218.
   PubMedGoogle Scholar
• Crim C, Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Willits LR, Yates JC, Vestbo J. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009 Sep; 34(3):641–647.
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK. Risk of pneumonia associated with long-term use of inhaled corticosteroids in COPD: A critical review and update. Curr Opin Pulm Med 2010 Mar; 16(2):118–122.
   Google Scholar
• Decramer M, Bartsch P, Pauwels R, Yernault JC. Management of COPD according to guidelines. A national survey among Belgian physicians. Monaldi Arch Chest Dis 2003 Jan–Mar; 59(1):62–80.
   PubMedGoogle Scholar
• Asche CV, Brixner DI, Conoscenti CS, Young DC, Shah H, Amy P. Assessment of physician prescribing for primary care patients with chronic obstructive pulmonary disease (COPD) in a national electronic medical record (EMR) research database [Abstract]. Chest 2006 Oct; 130(4):175S-b–175S.
   Web of Science ®Google Scholar
• Van Andel AE, Reisner C, Menjoge SS, Witek TJ. Analysis of inhaled corticosteroid and oral theophylline use among patients with stable COPD from 1987–1995. Chest 1999 Mar; 115(3):703–707.
   PubMed Web of Science ®Google Scholar
• Peperell K, Rudolf M, Pearson M, Diggle J. General practitioner prescribing habits in asthma/COPD. Asthma Gen Practice 1997 Dec; 5(2):29–30.
   Google Scholar
• De Miguel-Diez J, Carrasco-Garrido P, Rejas-Gutierrez J, Martin-Centeno A, Gobartt-Vázquez E, Hernandez-Barrera V, Gil de Miguel A, Jimenez-Garcia R. Inappropriate overuse of inhaled corticosteroids for COPD patients: impact on health costs and health status. Lung 2011 Jun; 189(3):199–206.
   PubMed Web of Science ®Google Scholar
• Roche N, Lepage T, Bourcereau J, Terrioux P. Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease. Eur Respir J 2001 Dec; 18(6):903–908.
   PubMed Web of Science ®Google Scholar
• Nadeem NJ, Taylor SJ, Eldridge SM. Withdrawal of inhaled corticosteroids in individuals with COPD –a systematic review and comment on trial methodology. Respir Res 2011 Aug; 12:107.
   PubMed Web of Science ®Google Scholar
• Rutschmann OT, Janssens JP, Vermeulen B, Sarasin FP. Knowledge of guidelines for the management of COPD: a survey of primary care physicians. Respir Med 2004 Oct; 98(10):932–937.
   PubMed Web of Science ®Google Scholar